L3VLUP
ProSign in

SRPT · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SRPTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SRPT
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSRPTJNJ
Q3 202011 holders, $3.1bn30 holders, $26.2bn
Q4 202013 holders, $4.0bn32 holders, $26.6bn
Q1 202111 holders, $1.3bn31 holders, $25.3bn
Q2 20219 holders, $1.0bn37 holders, $25.6bn
Q3 202110 holders, $1.2bn40 holders, $24.1bn
Q4 202113 holders, $1.2bn33 holders, $25.2bn
Q1 202212 holders, $1.1bn35 holders, $28.2bn
Q2 202213 holders, $946m33 holders, $26.9bn
Q3 202221 holders, $1.8bn36 holders, $25.4bn
Q4 202221 holders, $1.9bn35 holders, $27.6bn
Q1 202320 holders, $2.3bn42 holders, $24.5bn
Q2 202313 holders, $1.8bn38 holders, $25.0bn
Q3 202319 holders, $2.1bn37 holders, $18.9bn
Q4 202312 holders, $1.3bn31 holders, $19.0bn
Q1 202415 holders, $2.0bn32 holders, $19.7bn
Q2 202415 holders, $2.0bn35 holders, $20.4bn
Q3 202412 holders, $1.4bn28 holders, $22.3bn
Q4 20249 holders, $1.2bn37 holders, $20.4bn
Q1 202511 holders, $665m32 holders, $20.5bn
Q2 20255 holders, $175m31 holders, $18.4bn
Q3 20256 holders, $164m32 holders, $23.7bn
Q4 20257 holders, $298m29 holders, $27.8bn
Q1 20265 holders, $281m34 holders, $35.6bn
Q2 20265 holders, $132m33 holders, $39.1bn
SRPT

Sarepta Therapeutics Inc

Holders
15
Reported value
$2.0bn
Buyers
9
Sellers
5

Breadth +4 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SRPT (6)

Balyasny Asset Management LLC, Citadel Advisors LLC, ExodusPoint Capital Management LP, Farallon Capital Management LLC, PDT Partners LLC, Soros Fund Management LLC

Only JNJ (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →